Related Experiment Videos
Bone marrow transplantation for familial hemophagocytic lymphohistiocytosis
Insights
Familial hemophagocytic lymphohistiocytosis (FHL) is a fatal condition. Early bone marrow transplant may offer a treatment role for FHL, despite challenges like post-transplant sepsis.
Area of Science:
- Pediatric Hematology
- Immunology
- Oncology
Background:
- Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening hyperinflammatory syndrome.
- Early diagnosis and treatment are critical for improving outcomes in FHL.
Observation:
- A one-year-old child with FHL showed a partial response to etoposide.
- The patient relapsed and underwent a bone marrow transplant (BMT) with conditioning therapy.
- Complications including sepsis occurred post-transplant, leading to expiration.
Findings:
- Autopsy revealed residual FHL disease, indicating treatment limitations.
- Etoposide remains the primary agent with known efficacy for FHL.
- Bone marrow transplantation is a potential therapeutic option for FHL.
Implications:
- Early BMT should be considered in the management of FHL.
- Further research is needed to optimize FHL treatment strategies.
- Improving post-transplant care is crucial for FHL patients undergoing BMT.
Abstract:
A one year old child diagnosed at two months as having familial hemophagocytic lymphohistiocytosis had a partial response to etoposide. He relapsed and underwent a bone marrow transplant after conditioning with etoposide 65 mg/kg, total body irradiation and cyclophosphamide 60 mg/kg X 2 doses. Post transplant sepsis ensued and the patient expired. At autopsy residual disease was noted. Familial hemophagocytic lymphohistiocytosis continues to be a fatal disorder and etoposide is the only agent known so far with any efficacy. Bone marrow transplantation probably should be attempted early in its course and may have a role in the treatment of this disease.